1. Introduction
===============

There is a growing interest in the role of brain glutamate mechanisms in depression ([@bib10]), heightened by the observation that drugs altering glutamate activity such as the NMDA receptor antagonist, ketamine, and the glutamate release inhibitor, riluzole, may have beneficial effects in patients with treatment resistant depression ([@bib9]; [@bib19]).

Measuring glutamate activity in the brain in humans presents challenges but the use of magnetic resonance spectroscopy (MRS) provides a useful approach. Several studies have applied proton MRS to study glutamate levels in depression and overall the evidence suggests that acutely depressed patients have decreased levels of Glx (a composite measure of glutamate and glutamine) in anterior brain regions ([@bib1; @bib17; @bib18]). Interestingly a large MRS study of occipital cortex reported an opposite finding, namely that acutely depressed patients had increased glutamate levels ([@bib9]), suggesting potential regional brain differences in Glx regulation in depression.

In contrast, there have been few studies of Glx levels in recovered depressed patients but such information is important in determining the pathophysiological role of glutamate in vulnerability to depression. Our group found increased levels of Glx in occipital cortex in recovered unmedicated depressed patients ([@bib2]), consistent with the increased concentrations of glutamate reported in this brain region in acute depression. However, when we examined Glx levels in a subset of these participants in anterior cingulate cortex we found no difference between patients and controls ([@bib3]), again suggesting regional differences in Glx regulation in patients with mood disorder. [@bib16] also found normal Glx levels in anterior cingulate cortex in recovered depressed participants. The aim of the present study was to examine Glx levels in anterior cingulate cortex in a further group of recovered depressed patients. In addition, because levels of glutamate and glutamine can vary independently of each other we used a further MRS technique, PRESS-J, which permits measurement of glutamate without glutamine at moderate field strengths ([@bib6]).

2. Materials and methods
========================

2.1. Participants
-----------------

Medication-free, fully recovered patients with a history of recurrent major depressive disorder, diagnosed by the Structured Clinical Interview for DSM-IV (*n* = 14; 4M, 10F) and healthy controls (*n* = 16; 5M, 11F) were recruited. All were euthymic for at least three months, and had received no psychotropic medication within three months (mean = 38 months; range 8--84 months); three patients were drug naïve. Nine patients had a family history of mood disorder. Three of the recovered depressed patients had co-morbid illnesses; one had social phobia, and two subjects had a history of alcohol misuse but not dependence. On the day of scanning, mental state ratings were performed with the Hamilton Depression Rating Scale, Beck Depression Inventory, and Spielberger State and Trait Anxiety scales. All participants gave written informed consent to the study, which was approved by the Oxfordshire Research Ethics Committee, UK.

2.2. MRS methodology
--------------------

Scanning was performed on a 3T Varian INOVA system with a head optimised gradient coil (Tesla Engineering, Storrington, UK) and a head-only transmit/receive quadrature birdcage RF coil. Data were acquired from a 30 × 20 × 20 mm voxel placed in medial prefrontal and anterior cingulate cortex anterior to the genu of the corpus callosum. The voxel was positioned manually by reference to an axial T~1~-weighted gradient-echo image with the base of the voxel on a plane running through the genu and splenium of the corpus callosum.

PRESS data with water suppression (TE 26 ms, TR 3 s, 64 averages), and without (TE 26 ms, TR 3 s) were acquired. PRESS-J data ([@bib6]) with and without water suppression were similarly acquired with TE arrayed from 35 ms to 185 ms in 10 ms increments (water-suppressed data, total acquisitions = 128; non-water suppressed data, total acquisitions = 16; TR = 3 s). T~1~-weighted structural images of whole brain were acquired with 2 mm^3^ voxel resolution.

PRESS data were analysed with LCModel software ([@bib8]), using the non-water suppressed data for eddy current correction, calculating metabolite concentrations relative to creatine in conventional fashion using metabolite basis spectra (alanine, aspartate, creatine, GABA, glucose, glutamine, glutamate, glycerophosphocholine, phosphocholine, lactate, myo-inositol, N-acetylaspartate, N-acetylaspartylglutamate, scyllo-inositol, taurine) and simulated lipid and macromolecule components. PRESS-J spectra were zero-order phased, apodised with a 5 Hz Gaussian filter, and summed ([@bib6]) before analysis. Glutamate levels relative to creatine were measured using AMARES (Advanced method for accurate, robust and efficient spectral fitting) ([@bib12]) since metabolite basis spectra were not available for PRESS-J acquisitions, and the spectral simplification and flat baselines obtained with this technique in vivo make direct single peak fitting reliable ([@bib6]). Concentrations in proton MRS studies are conventionally expressed relative to creatine which acts as an internal reference standard in the voxel (see for example, [@bib9]; [@bib16]); levels relative to tissue water were also calculated but not included here for reasons of space.

FSL FAST ([@bib13]) was employed to segment the structural brain images into grey matter, white matter, and CSF, to allow estimation of voxel composition.

2.3. Statistical analysis
-------------------------

Statistical analyses were performed in SPSS version 15. To guard against type I error, the available MRS measures (Glx, glutamate, myo-inositol, choline, and N-acetylaspartate) were initially compared between groups by multivariate analysis using Wilks\' lambda. Two-tailed univariate analysis for each measure independently was then performed to identify the basis of any overall group effect. The sensitivity of effects to the inclusion or exclusion of covariates (age and voxel composition) was tested. Group demographics and clinical characteristics were compared by *t*-test. Power calculations indicated that a sample size of 30 would have 80% power to detect a 10% difference in Glx/Cr between groups at 0.05 significance level. This is the size of difference typically seen in studies of depressed patients ([@bib1; @bib17; @bib18]).

3. Results
==========

Participants with previous episodes of major depression did not differ significantly from controls in age, or on ratings of current symptoms of depression or anxiety ([Table 1](#tbl1){ref-type="table"}). There was a higher level of trait anxiety reported in those with previous depressive illness (36.2 ± 2.6 vs 30.1 ± 1.3, *p* = 0.04).

The voxels measured contained predominantly grey matter (69%). Multivariate analysis of MRS results revealed a significant difference between the groups (Wilks\' lambda = 0.624, *F*(5,24) = 2.894, *p* = 0.035). However this difference was not explained by glutamatergic abnormalities, since levels of Glx and glutamate did not differ between groups (*p* \> 0.2 in both cases; [Fig. 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). Interestingly, myo-inositol levels were significantly elevated in those with a history of major depressive disorder (*F*(1,28) = 7.49, *p* \< 0.02; [Fig. 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). The elevation of myo-inositol was robust to inclusion of age and voxel composition as covariates (*F*(1,24) = 7.611, *p* \< 0.02). The groups did not differ on other MRS measures (NAA, choline, creatine), nor in voxel composition (*p* \> 0.1 in each case, [Table 1](#tbl1){ref-type="table"}). All findings were robust to the inclusion of voxel grey and white matter composition as covariates.

4. Discussion
=============

Our findings suggest that both Glx (glutamate and glutamine) and glutamate alone as measured by proton MRS at 3T are normal in the anterior cingulate cortex of recovered depressed patients withdrawn from medication. Therefore, based on the results of studies in acutely depressed patients, we conclude that the low Glx concentration in anterior brain regions detected by MRS is likely to be a state marker of acute depression. This contrasts with findings in occipital cortex, where levels are apparently elevated in both acutely ill and recovered depressed patients ([@bib2; @bib9]).

In some contexts, Glx estimates include a small component (\< 10%) attributable to GABA ([@bib10]). Reports conflict as to whether reduced levels of GABA are found in the anterior cortex of recovered depressed patients ([@bib3; @bib16]). In the absence of specific GABA measurements, the data reported here cannot clarify this point since, at most, the reduction in GABA would be reflected by a 1% difference in Glx levels which is beyond the statistical power of this study.

The conclusion that glutamatergic abnormalities in anterior brain regions are markers of the acute depressive state should be treated as tentative until further studies can be performed. For example, the current group of recovered depressed patients was not demonstrated to have lowered glutamate levels in anterior cingulate cortex when acutely depressed. In particular our data cannot exclude the possibility that persistent glutamatergic abnormalities exist in a subgroup of patients. These questions could be clarified by a larger longitudinal study of these measures in depressed patients at different phases of their illness.

MRS metabolite concentrations in this study were expressed relative to creatine, which is conventional when proton MRS is used. However, this is unlikely to have affected the study conclusions since analyses referencing to tissue water found the same pattern of findings (data not shown). It is quite possible that more subtle abnormalities in glutamate mechanisms, for example in glutamate receptor populations could be present in recovered depressed patients but not detectable by MRS ([@bib10]). Why recovered depressed patients should apparently have persistent increases in Glx in occipital cortex ([@bib2]) is not clear at present.

Our finding of elevated levels of myo-inositol in the recovered depressed patients was unexpected. In previous studies of anterior cingulate cortex in acute depression, one study with participants of a similar age range to those described here ([@bib5]) found decreased myo-inositol, whereas two studies in older populations found no significant difference ([@bib1; @bib7]). Similarly, in studies using voxels placed predominantly in frontal white matter, those with similar age ranges to the current study found lower levels of myo-inositol in acute depression ([@bib14; @bib15]), whereas levels were elevated in a more elderly sample ([@bib7]). The reason for this apparent effect of age on myo-inositol levels in depression in not known, although it has been hypothesised that it may reflect increased probability of reactive gliosis in more elderly populations ([@bib5]).

Inositol and related compounds have an important role as intracellular second messengers; however the MRS-visible signal in brain appears predominantly to reflect myo-inositol actively accumulated within astrocytes where it is employed as an osmolyte ([@bib4]). Thus elevated myo-inositol, as well as normalised glutamate and glutamine, after recovery from depression may reflect changes in glial function. Glia plays a key role in the regulation of glutamate neurotransmission though the process of glutamate--glutamine cycling ([@bib10]), making it possible that changes in this process during recovery from depression might account for both normalisation of Glx levels and increases in myo-inositol. This hypothesis could be tested by using carbon-13 MRS which permits the measurement not only of overall glutamate levels, but also rates of glutamate--glutamine cycling through glia ([@bib11]).
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###### 

Group characteristics.

                                                                Recovered depression (*n* = 14)   Controls (*n* = 16)
  ------------------------------------------------------------- --------------------------------- ----------------------------------------------
  Age (mean and range)                                          32.6 (18--57)                     31.8 (19--63)
  Gender                                                        4M, 10F                           5M, 11F
  Smoking history                                               5 smokers                         3 smokers
  Beck Depression Inventory                                     2.7 (3.1)                         1.4 (1.5)
  Hamilton Depression Rating Scale                              0.3 (0.5)                         0.1 (0.5)
  Spielberger Trait Anxiety                                     36.2 (9.7)                        30.1 (5.3)[⁎](#tblfn1){ref-type="table-fn"}
  Spielberger State Anxiety                                     31.5 (8.7)                        30.9 (6.2)
  Age of onset                                                  22 (10.8)                         
  Number of episodes                                            2.6 (1.2)                         
  Lifetime melancholic depression                               3                                 
  Lifetime history of suicide attempts                          6                                 
  Months since last antidepressant treatment (mean and range)   38 (8--84)                        
  Glx/creatine                                                  1.61 (0.15)                       1.69 (0.21)
  Myo-inositol/creatine                                         0.86 (0.07)                       0.78 (0.09)[⁎](#tblfn1){ref-type="table-fn"}
  N-acetylaspartate/creatine                                    1.08 (0.09)                       1.11 (0.15)
  Choline/creatine                                              0.31 (0.04)                       0.29 (0.02)
  Glutamate/creatine                                            1.58 (0.23)                       1.66 (0.16)

Mean values with standard deviation unless otherwise stated.

*p* \< 0.05 *t*-test.
